Note: The NCCN recommendation applies to all high emetic risk anticancer agents; the Enhertu HCP site applies it because the product is classified as highly emetogenic. The table columns are Days 1 to 4; the letters after drug names are footnote markers on the source page. The site's reference list gives an access date of April 3, 2026, for the NCCN Guidelines for Antiemesis V.1.2026.